Leucine-Restricted Diet With Chemotherapy for Gastric Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy drugs can help treat locally advanced gastric cancer before surgery. The goal is to see if this combination is safe and more effective than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Gastric cancer confirmed by biopsy (tissue sample), with no cancer spread to distant organs
- Age 18–70 years old
- Able to eat by mouth or receive nutrition through a feeding tube
- No other active cancers besides gastric cancer
- Willing to follow a special low-leucine diet during treatment
- No severe diabetes, chronic diarrhea, vomiting, or stomach bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a diet low in leucine (an amino acid) can help treat gastric cancer before surgery. It aims to see if it's safe and effective for patients who are preparing for tumor removal.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.